logo-loader
viewArc Minerals Limited

Arc Minerals excites investors as it updates on Kalaba exploration

“A number of holes have intersected pervasive mineralisation with visible copper and cobalt over thicknesses of 80m which is particularly exciting"

trader
Arc shares gained 0.51p or 12.18% changing hands at 4.74p

Arc Minerals Ltd (LON:ARCM) shares advanced as it revealed the findings of a drill programme on the Kalaba prospect, part of the Zamsort copper-cobalt project.

The company said the programme is progressing well, with ten drill holes to date completed for a total of 1,435 metres.

WATCH: Arc Minerals ups stake in Zamsort, kicks off new drilling

First results are expected over the next few weeks, though the company said that three holes had intersected visible mineralisation for more than 80 meters - in one of those holes, the mineralisation started six metres from surface.

"I am very pleased with the progress of the drilling programme to date,” said Nick von Schirnding, executive chairman.

“A number of holes have intersected pervasive mineralisation with visible copper and cobalt over thicknesses of 80m which is particularly exciting. 

“I look forward to updating on the progress of the initial assay results as well as the RC drilling programme which will commence imminently."

Arc told investors that it is currently working on the logging, core cutting as well as sample preparation and sending the samples to the laboratory for multi-element testing.

In London, Arc shares gained 0.51p or 12.18% changing hands at 4.74p.

Quick facts: Arc Minerals Limited

Price: 2.8 GBX

AIM:ARCM
Market: AIM
Market Cap: £20.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 19 minutes ago

2 min read